Are you the publisher? Claim or contact us about this channel


Embed this content in your HTML

Search

Report adult content:

click to rate:

Account: (login)

More Channels


Channel Catalog


Channel Description:

Cell Culture market research products provide analysis of the latest trends, developments and market data for this industry. Research information will help you make informed business decisions.

(Page 1) | 2 | 3 | .... | 17 | newer

    0 0

    THIS REPORT CONTAINS Total worldwide sales revenues for media, sera, and reagent used in the biotechnology were $2,546.2million in 2010, and are expected to increase to more than $3800 Million in 2015, at a compound annual growth rate (CAGR) of 8.7%. The largest biotechnology segments in 2010 were Reagents. All Reagents in Biotechnology will increase from $1,066.6 million in 2010 to nearly $1,850.4 million in 2015, at a compound annual growth rate (CAGR) of 11.6%. Sales of Media will experience high growth. This market segment was worth $821.8 million in 2010 and will increase at a 8.6% compound annual growth rate (CAGR) to reach a value of $1,242.4 million in 2015. Sales of Sera will experience moderate growth. This market segment was worth $31657.8 million in 2010 and will increase at a 3.3% compound annual growth rate (CAGR) to reach a value of $772.5 million in 2015.

    0 0

    Therapeutic Protein Production: A Changing Landscape examines the implications of and advances in upstream and downstream operations used in the production of therapeutic proteins. Improvements in protein yields per unit volume, the significance of introducing disposables throughout the process and the shift to animal extracts-free culture media are three of the major themes covered by this report. The impact of global competition, lower barriers to entry and the shift in the production bottleneck from upstream to downstream unit operations are presented together with likely shifts impacting the production outlook over the next five years. More than a dozen tables and figures in this report summarize the report’s findings. Some of the topics highlighted in the report: Pros and cons of animal cell culture Development of alternative production cell lines Improving protein production per volume of culture media Impact of disposables on cost and availability of proteins Bottlenecks appear on the downstream side of production Shift away from capital spending on fixed, reusable infrastructure Tackling biosimilar regulatory questions Dimensions of Asian and EU competition

    0 0

    The growth and propagation of mammalian cells in culture is a routine but critical precursor to the investigation of such fundamental cellular processes as gene expression and protein function and to the development of therapeutics. Cell culture products are widely used not only by scientists working with traditional cell lines but also by researchers engaged in experiments with such emerging model systems as stem cells and engineered cell lines. This Cell Culture Dashboard was developed based upon the aggregated responses to a 22-question survey completed by more than 480 scientists actively engaged in mammalian cell culture predominantly located in North America and Europe. This Dashboard reveals key market indicators for the research market for cell culture products as a whole as well as for the following product segments: Basal media Fetal bovine serum Animal sera Balanced salt solutions Serum free media Dry powdered media Growth and attachment factors Percepta’s 2010 Cell Culture Dashboard™ the third in a series of reports that examines the characteristics and dynamics of the market for cell culture products. This 2010 Dashboard provides a snapshot of the current market landscape that

    0 0

    Microorganisms are ubiquitous and may be found in almost every environment on earth. As such, they are a diverse group with an assortment of genotypic and phenotypic features and varying growth and reproduction requirements. There is continual interaction between humans and microbes, ranging from disease-causing pathogenic organisms invading the human body to microorganisms harnessed by humans to aid in the fermentation of food products. The detection and characterization of these organisms enables us to better understand how to manipulate and exert some control over their impact on our lives and welfare. This TriMark Publications report describes the specific segment of the in vitro diagnostics (IVD) market known as the diagnostic microbiology and focuses primarily on the automated microbial testing systems. Within medical diagnostics, automated microbial testing for infectious disease-causing organisms offers one of the brightest areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics--as well as the development of microarray devices--have led the microbiology market to accept the power of advanced analytical techniques for the diagnosis and treatment of infectious disease. For this analysis, the automated microbial testing market has been divided into the following segments for this examination: 1) microbial detection, 2) microbial enumeration, 3)

    0 0
  • 09/30/10--22:00: Cell/Tissue Culture Supplies
  • This report analyzes the worldwide markets for Cell/Tissue Culture Supplies in US$ Million by the following Product Segments: Media, Sera, and Reagents. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Latin America. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets.The report profiles 131 companies including many key and niche players such as Affymetrix, Inc., AMRESCO, Inc., BD Biosciences, Cell Culture Technologies, LLC, Cell Essentials, Inc., Irvine Scientific, Life Technologies Corporation, Lonza Biologics Plc, Mediatech, Inc., Millipore Corporation, Medi-Cult A/S, MP Biomedicals, PerBio Science AB, PromoCell GmbH, Sera Laboratories International, Sigma-Aldrich Corporation, SAFC Biosciences, and Vitrolife AB. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources. Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing

    0 0

    Now that the majority of screening assays employ the use of cell-based technologies, robust cell-based assays are essential for lead identification and the optimisation of therapeutic candidates. Factors including the ever increasing numbers of compound failures and rapidly escalating costs of R&D are driving the uptake of increasingly biologically relevant surrogates in cell-based assays to predict the response of drug candidates - leading to developments in areas including stem cell use in screening programmes, 3D cell cultures and label-free detection. These technologies, and the effective techniques and methods employed in their use have been progressing at breakneck speed and this conference will assemble leading experts from both industry and academia to present you with the latest updates, technologies and critical strategies in a practical, case study focused environment. Hear about new techniques, technologies and methods used in cell-based assays Discuss the use of stem cells in discovery and development Explore the powers of RNAi screening in target discovery and biomarker identification Learn from multiple case studies demonstrating real life data and processes that work Network with key

    0 0

    This report provides an overview of the life sciences research tools market from 2005 to 2015. Life sciences research tools companies offer instruments and reagents to laboratory scientists. Top vendors include ThermoFisher, Life Technologies (Invitrogen / Applied Biosystems), Sigma-Aldrich and Millipore. We divided this market in 5 broad segments: 1) pure genomics technologies (PCR, qPCR, digital PCR, CE sequencing, next generation sequencing (NGS) / third generation sequencing (3GS), microarrays, molecular biology tools), 2) pure proteomics technologies (protein isolation and analysis, ELISA, protein production, western blots and protein microarrays), 3) cell biology technologies (basic cell biology reagents, discovery services, media and sera, flow cytometry, transfection and electroporation, microscopy and automation, whole cell imaging, cell culture equipment, cells and tissues, high content imaging), 4) other analytical technologies (liquid chromatography, mass spectroscopy, in vivo study, sample preparation, multiplex technologies, magnetic beads) and 5) lab supplies and disposables. For each of these 29 subsegments, we present an analysis detailing sales of instruments and reagents from 2005 to 2015. In addition, we detail market drivers and moderators, market trends, a high level end-customer breakdown (Academic, BioPharma and Applied markets customers) and key competitors. Many of these technologies are increasingly used for

    0 0

    The global blood plasma-derived products market has shown consistent growth over the period 2002-2009 and the rapid increase in cases of Hemophilia, low treatment cost to patients and rising ageing population are the major factors that will be driving the market for plasma-derived products in coming years. Immunoglobulin (IVIG) and albumin account for the largest share of the global plasma market. The demand for blood albumin has increased over the years due to growing usage of albumin as a cell culture medium ingredient, antioxidant and also as the most effective volume expander in critical care conditions such as liver disease and hemorrhagic stroke. Another significant factor in albumin demand has been growing needs from emerging markets like China which has started importing albumin from Western companies. CSL and Baxter currently are the biggest plasma fractionation companies. Factor VIII account for a major portion of plasma-derived clotting factor and lack of which causes Hemophilia A. Demand for genetically engineered recombinant Factor VIII (rFVIII) is also increasing as they carry less risk of carrying viral strains and plasma-borne diseases. Baxter has the largest market share in rFVIII market. The present report offers an analysis of the global

    0 0

    This report analyzes the worldwide markets for High Throughput Screening (HTS) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets. The report profiles 103 companies including many key and niche players such as Agilent Technologies Inc., BIOCIUS Life Sciences, Inc, Aurora Biomed Inc., Axxam SpA, Beckman Coulter, Inc., BioFocus DPI Ltd., Bio-Rad Laboratories, Inc., BMG LABTECH GmbH, Caliper Life Sciences, Inc., Corning Inc., DiscoveRx Corporation, EVOTEC BioSystems, ForteBio, Inc., Genedata AG, IntelliCyt Corporation, Life Technologies Corporation, Luminex Corporation, Molecular Devices Inc., PerkinElmer Inc., Roche Applied Sciences, Sigma-Aldrich Corporation, and Tecan Group Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources. Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The

    0 0

    Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing Summary GBI Research, the leading business intelligence provider, has released its latest research report, “Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing”, which provides insights into the production methods of vaccines and into vaccine production capacity. The report discusses the egg-based and cell culture-based vaccine manufacturing processes in depth. Furthermore, details of the whole process throughput and the technologies used in vaccine manufacturing are provided in the report. It also offers a clear view of the regulatory landscapes of the US, Europe and Japan. It includes profiles of the key players and the alliances which exist in the world of vaccine manufacturing. The report explores the emerging technologies, drivers and barriers of the vaccine manufacturing process and the challenges and unmet needs present in the market. GBI Research analysis suggests that Singapore and China are emerging as the biggest hot spots for the future of vaccine manufacturing, along with India. The vaccine manufacturing market of Singapore is growing at a rate of around 20%. Furthermore, regulatory support from the governments of these three countries is high. The in depth analysis of the report is based on propriety databases, primary

    0 0

    Several cell culture-derived biopharmaceutical drugs were launched in the US and European markets in 2010. Biopharmaceuticals (recombinant proteins, monoclonal antibody and nucleic acid-based products) represent the fastest growing sector in the pharmaceutical industry. Driving the extraordinary interest in biopharmaceuticals is the ability of these large proteins to target diseases in a very specific manner, thus maximizing efficacy while minimizing side effects. Growth in the development and production of biopharmaceuticals is the most significant driver of the cell culture market. Biological products are developed from large and complex protein molecules, which require equally complex manufacturing methods and an array of analytical techniques. Protein-based biopharmaceuticals are invariably produced by an initial cell culture step (upstream processing), followed by product recovery, purification and formulation into final product format (downstream processing). This report analyzes the world market for the cell cultures used in these steps and the major trends driving this market. Forecasts and current market sizing are provided in three specific segments: Media, Sera, and Reagents In addition to a thorough discussion of the technologies and techniques currently employed and emerging in the cell culture area, Kalorama's exhaustive report provides specific information on:

    0 0

    Now that the majority of screening assays employ the use of cell-based technologies, robust cell-based assays are essential for lead identification and the optimization of therapeutic candidates. Factors including the ever-increasing numbers of compound failures and rapidly escalating costs of R&D are driving the uptake of increasingly biologically relevant surrogates in cell-based assays to predict the response of drug candidates; leading to developments in areas including stem cell use in screening programmes, 3D cell cultures and label-free detection. These technologies, and the effective techniques and methods employed in their use have been progressing at breakneck speed and this conference will assemble leading experts from both industry and academia to present you with the latest updates, technologies and critical strategies in a practical, case-study focused environment. Cell-Based Assays is the place for senior scientists from assay development, pharmacology, screening and related fields to meet and discuss progress in the area and exchange ideas moving forward. A dual focus on both strategic and regulatory concerns, alongside more specific scientific and technical analysis, supported with extensive case studies, ensures a truly comprehensive treatment of the most important issues. The event will consist of a two-day

    0 0

    As the premier market research firm in the life science industry, few companies are as qualified as BioInformatics LLC to take on the task of determining the top supplier companies in 29 product and service categories. Over 6,000 life scientists from BioInformatics LLC’s online panel, The Science Advisory Board, participated in the nomination and voting process for the 2011 Life Science Industry Awards. The awards were announced and summary results released on November 15, 2011. But going beyond the summary of results, life science suppliers will want to put these key findings into action. Therefore, in addition to calculating the popular vote, the data collected was analyzed by BioInformatics LLC to yield findings that life science suppliers can use. Titled Brand Performance in the Life Science Industry, this deep dive into the results of the Life Science Industry Awards market study will enable life science suppliers to assess their own rankings in the industry, benchmark their performance against the competition and gain insight as to brand awareness, market position and overall satisfaction with products and supplier attributes. Here at BioInformatics LLC, we put our extensive expertise behind creating an industry award that not

    0 0

    Seasonal Influenza Vaccine Market in Asia-Pacific Region - Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity Summary GBI Research, the leading business intelligence provider has released its latest research “Seasonal Influenza Vaccine Market in Asia-Pacific Region - Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity Description” which essentially provides insights into the seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2017. The report also delves deep into vaccination patterns for seasonal influenza in the Asia-Pacific Region. Further, the geographical distribution of seasonal influenza vaccines across Japan, Australia, New Zealand, China, Taiwan, Philippines, Hong Kong, Malaysia, India and Singapore are also provided in the report. The report offers a clear view of the regulatory landscape in the Asia-Pacific countries. The report also reveals the seasonal influenza vaccine R&D pipeline and offers profiles of promising vaccines. The report explores the competitive landscape including profiles for top companies. Finally, the key trend analysis on mergers and acquisitions, and licensing agreements involving seasonal influenza vaccines is also presented. Treatment of seasonal influenza is dominated by two categories of treatment options, vaccines and antiviral therapies.

    0 0

    What does the future hold for cell-based assays in pharma? Visiongain's report shows you potential revenues and other trends, with data, forecasts and discussions. Our study analyses products and services for cell-based testing. It covers activities of product developers and pre-clinical contract research organisations. You discover sales predictions to 2022 at world market, main submarket and national levels. Find potential revenues for products and services. Also, you receive discussions of many companies in the cell assay industry, seeing their activities and outlooks. Companies featured include the following: BD Biosciences Life Technologies PerkinElmer Beckman Coulter Evotec GE Healthcare Thermo Fisher Scientific Covance PPD Charles River Laboratories MD Biosciences. Looking ahead to 2022, many commercial opportunities exist for cell-based testing. Our report gives you business research and analysis there. Where are cellular assays heading? Greater need for cellular information earlier in pre-clinical product development stimulates demand for the tests. Our report shows you how their use is increasing in drug discovery and development. Which developmental processes will benefit most from cell assays? This decade, drug screening and toxicity testing will be important applications for cell-based products and services, our analysis shows.

    0 0

    This report analyzes the worldwide markets for High Throughput Screening (HTS) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets. The report profiles 103 companies including many key and niche players such as Agilent Technologies Inc., Aurora Biomed Inc., Axxam SpA, Beckman Coulter, Inc., BioFocus DPI Ltd., Bio-Rad Laboratories, Inc., BMG LABTECH GmbH, Caliper Life Sciences, Inc., Corning Inc., DiscoveRx Corporation, EVOTEC BioSystems, ForteBio, Inc., Genedata AG, IntelliCyt Corporation, Life Technologies Corporation, Luminex Corporation, Molecular Devices Inc., PerkinElmer Inc., Roche Applied Sciences, Sigma-Aldrich Corporation, and Tecan Group Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting

    0 0
  • 02/29/12--21:00: Cell-Based Assays
  • This report analyzes the worldwide markets for Cell-Based Assays in US$ Million by the following Product Segments: Assay Kits (Functional Assays, Cell Death-Associated Assays, & Cell Growth-Associated Assays), and Laboratory Automation. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 73 companies including many key and niche players such as BD Biosciences, Beckman Coulter, Inc., BioVision, Inc., Caliper Life Sciences, Inc., Cisbio Bioassays, DiscoveRx Corporation, EMD Millipore, Enzo Life Sciences, Inc., Evotec AG, GE Healthcare Life Sciences, Life Technologies Corp., New England Biolabs Inc., PerkinElmer, Inc., Promega Corporation, ProQinase GmbH, Qiagen NV, Sigma-Aldrich, StemCells, Inc., Thermo Fisher Scientific, Inc., and Xenometrix AG. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to

    0 0
  • 03/31/12--22:00: Marine Biotechnology
  • This report analyzes the Global markets for Marine Biotechnology in US$ Million by the following Product Segments: Marine Biomaterials, Marine Bioactive Substances, and Others. The major End-Use Applications analyzed are Industrial Products, Health Care/Biotechnology, Consumer Products, Public Services & Infrastructure, and Others. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for this market. The report profiles 87 companies including many key and niche players such as Aker BioMarine ASA, Ashland Inc., CP Kelco US, Inc., Cyanotech Corp., Elan Corp, FMC Corp., FMC Biopolymers AS, GlycoMar Ltd., Lonza Group Ltd., MariCal, Marinova, Mera Pharmaceuticals Inc., New England Biolabs Inc., PharmaMar S.A, PML Applications Ltd., Prolume Ltd., Royal DSM N.V, Sea Run Holdings Inc., and Tequesta Marine Biosciences. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom

    0 0

    The global market for media, sera and reagents used in biotechnology was valued at $2.3 billion in 2009, $2.5 billion in 2010 and is estimated to have reached nearly $2.8 billion at the end of 2011. The market is expected to reach $4.2 billion by 2016, a compound annual growth rate (CAGR) of 8.8%. The Asian market segment for cell culture products was valued at $236 million in 2009 and $273 million in 2010. This market is expected to increase from $312.5 million in 2011 to $637 million by 2016, a CAGR of 15.3%. The Asian market segment for cell culture media was valued at $97.3 million in 2009 and reached $119.9 million in 2010. This market is expected to increase from $143.8 million in 2011 to $359.4 million by 2016, a CAGR of 20.1%.

    0 0

    The global market for media, sera and reagents used in biotechnology was valued at $2.3 billion in 2009, $2.5 billion in 2010 and is estimated to have reached nearly $2.8 billion at the end of 2011. The market is expected to reach $4.2 billion by 2016, a compound annual growth rate (CAGR) of 8.8%. The U.S. market segment for cell culture products was $1.3 billion in 2009 and $1.4 billion in 2010. This market is expected to increase from $1.5 billion in 2011 to nearly $2.3 billion by 2016, at a CAGR of 8.3%. The U.S. market segment for cell culture media was $399.2 million in 2009 and $427.7 million in 2010. This market is estimated to increase from $460.3 million in 2011 to $655.5 million by 2016, a CAGR of 7.3%.

(Page 1) | 2 | 3 | .... | 17 | newer